Truist Financial Boosts Pediatrix Medical Group (NYSE:MD) Price Target to $16.00

Pediatrix Medical Group (NYSE:MD) had its target price upped by Truist Financial from $13.00 to $16.00 in a research report released on Monday morning, Benzinga reports. Truist Financial currently has a hold rating on the stock.

A number of other research firms have also weighed in on MD. Mizuho raised their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday. Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their price target for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, UBS Group raised their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a research report on Friday, August 9th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Up 4.6 %

Pediatrix Medical Group stock opened at $16.06 on Monday. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $16.41. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -5.25, a price-to-earnings-growth ratio of 2.35 and a beta of 1.55. The firm’s fifty day moving average price is $11.89 and its two-hundred day moving average price is $9.54. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period last year, the firm earned $0.29 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts predict that Pediatrix Medical Group will post 1.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO C Marc Richards sold 17,438 shares of Pediatrix Medical Group stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the transaction, the chief financial officer now owns 175,347 shares in the company, valued at $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 68,100 shares of company stock valued at $701,889. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in Pediatrix Medical Group by 79.2% during the first quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock valued at $419,000 after acquiring an additional 18,438 shares in the last quarter. Empowered Funds LLC grew its stake in Pediatrix Medical Group by 8.2% in the 1st quarter. Empowered Funds LLC now owns 235,124 shares of the company’s stock worth $2,358,000 after buying an additional 17,784 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in Pediatrix Medical Group by 4.5% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 72,767 shares of the company’s stock worth $730,000 after buying an additional 3,142 shares in the last quarter. Illinois Municipal Retirement Fund grew its stake in Pediatrix Medical Group by 8.8% in the 1st quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock worth $497,000 after buying an additional 4,013 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after buying an additional 1,167 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.